

Product Data Sheet

Product Name: R-268712

Cat. No.: GC32840

Chemical Properties

Cas. No. 879487-87-3

SMILES FC1=C(C2=CN(CCO)N=C2)C=C(C3=CNN=C3C4=CC=CC(C)=N4)C=C1


Formula $C_{20}H_{18}FN_5O$ M.Wt 363.39

Solubility DMSO : 125 mg/mL (343.98 mM) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

R-268712 is a potent and selective inhibitor of ALK5 with an IC₅₀ of 2.5 nM. IC₅₀ value: 2.5 nM [1] Target: ALK5 in vitro: R-268712 is a novel and specific inhibitor of activin receptor-like kinase 5 (ALK5), a transforming growth factor β (TGF- β) type I receptor. R-268712 is a potent and selective inhibitor of ALK5 with an IC₅₀ of 2.5 nM, an approximately 5000-fold more selectivity for ALK5 than

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

p38 mitogen-activated protein kinase (MAPK). R-268712 is a weak inhibitor of p38 MAP kinase (IC₅₀: 12.1 μ M). [1] in vivo: Oral administration of R-268712 at doses of 1, 3 and 10 mg/kg also inhibited the development of renal fibrosis in a dose-dependent manner in a unilateral ureteral obstruction (UUO) model. [1]

[1]. Terashima H, et al. R-268712, an orally active transforming growth factor- β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Eur J Pharmacol. 2014 Jul 5;734:60-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA